Assessment of Knowledge and General Attitudes of Primary Care Physicians Toward Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Drugs in the Management of Type 2 Diabetes Mellitus in the Qassim Region. [PDF]
Aljulajil F, Rabbani U.
europepmc +1 more source
Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan +5 more
wiley +1 more source
Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. [PDF]
Kaku K +4 more
europepmc +1 more source
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao +4 more
wiley +1 more source
Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats. [PDF]
Chayah M +7 more
europepmc +1 more source
Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike +10 more
wiley +1 more source
Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study. [PDF]
Itsukaichi A +7 more
europepmc +1 more source
DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient. [PDF]
Usami J, Takezawa Y.
europepmc +1 more source
Adaptive islet biology and incretin physiology provide a framework linking diverse diabetes phenotypes, with advances in β‐cell stress adaptation, intra‐islet communication, receptor‐resolved biology, and β‐cell mass imaging. By integrating clinical perspectives from Asia and Europe with multiscale islet‐cell biology, these insights may support ...
Takaaki Murakami +5 more
wiley +1 more source
DPP-4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. [PDF]
Harris DD +7 more
europepmc +1 more source

